Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer

Journal of Clinical Investigation

Volumn 124, Issue 12, 2014, Pages 5466-5480

  Eruslanov, Evgeniy B ^a   Bhojnagarwala, Pratik S ^a   Quatromoni, Jon G ^a   Stephen, Tom Li ^b   Ranganathan, Anjana ^a   Deshpande, Charuhas ^a   Akimova, Tatiana ^a   Vachani, Anil ^c   Litzky, Leslie ^a   Hancock, Wayne W ^a   Conejo Garcia, José R ^b   Feldman, Michael ^a   Albelda, Steven M ^c   Singhal, Sunil ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b WISTAR INSTITUTE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD137 LIGAND; CD86 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; INTERLEUKIN 8; L SELECTIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; OX40 LIGAND; CHEMOKINE RECEPTOR; CYTOKINE; LEUKOCYTE ANTIGEN;

ARTICLE; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; CYTOKINE RELEASE; HUMAN; HUMAN CELL; LUNG CANCER; LUNG RESECTION; LYMPHOCYTE PROLIFERATION; NEUTROPHIL; PHENOTYPE; T LYMPHOCYTE; TUMOR ASSOCIATED NEUTROPHIL; TUMOR MICROENVIRONMENT; UPREGULATION; CELL PROLIFERATION; CLINICAL TRIAL; IMMUNOLOGY; LEUKOCYTE ACTIVATION; LUNG TUMOR; MALE; PATHOLOGY;

ANTIGENS, CD; CELL PROLIFERATION; CYTOKINES; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; NEUTROPHIL ACTIVATION; NEUTROPHILS; RECEPTORS, CHEMOKINE; T-LYMPHOCYTES;

EID: 84915748819     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI77053     Document Type: Article

References (67)

1. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell. 2005;7(3):211-217.
2. Sica A, et al. Origin and functions of tumor-associated myeloid cells (TAMCs). Cancer Microenviron. 2012;5(2):133-149.
3. Heusinkveld M, van der Burg SH. Identification and manipulation of tumor associated macrophages in human cancers. J Transl Med. 2011;9:216.
4. Galdiero MR, Garlanda C, Jaillon S, Marone G, Mantovani A. Tumor associated macrophages neutrophils in tumor progression. J Cell Physiol. 2013;228(7):1404-1412.
5. Brandau S, Dumitru CA, Lang S. Protumor and antitumor functions of neutrophil granulocytes. Semin Immunopathol. 2013;35(2):163-176.
6. Houghton AM. The paradox of tumor-associated neutrophils: Fueling tumor growth with cytotoxic substances. Cell Cycle. 2010;9(9):1732-1737.
7. Piccard H, Muschel RJ, Opdenakker G. On the dual roles and polarized phenotypes of neutrophils in tumor development and progression. Crit Rev Oncol Hematol. 2012;82(3):296-309.
8. Fridlender ZG, et al. Polarization of tumor-associated neutrophil phenotype by TGF-β: "N1" versus "N2" TAN. Cancer Cell. 2009;16(3):183-194.
9. Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. J Immunol. 2004;172(5):2731-2738.
10. Seok J, et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A. 2013;110(9):3507-3512.
11. Trellakis S, et al. Polymorphonuclear granulocytes in human head and neck cancer: enhanced inflammatory activity, modulation by cancer cells and expansion in advanced disease. Int J Cancer. 2011;129(9):2183-2193.
12. Jensen HK, Donskov F, Marcussen N, Nordsmark M, Lundbeck F, von der Maase H. Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. J Clin Oncol. 2009;27(28):4709-4717.
13. Jensen TO, et al. Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma. Cancer. 2012;118(9):2476-2485.
14. Li YW, et al. Intratumoral neutrophils: A poor prognostic factor for hepatocellular carcinoma following resection. J Hepatol. 2011;54(3):497-505.
15. Rao HL, et al. Increased intratumoral neutrophil in colorectal carcinomas correlates closely with malignant phenotype and predicts patients' adverse prognosis. PLoS One. 2012;7(1):e30806.
16. Caruso RA, Bellocco R, Pagano M, Bertoli G, Rigoli L, Inferrera C. Prognostic value of intratumoral neutrophils in advanced gastric carcinoma in a high-risk area in northern italy. Mod Pathol. 2002;15(8):831-837.
17. Carus A, Ladekarl M, Hager H, Pilegaard H, Nielsen PS, Donskov F. Tumor-associated neutrophils and macrophages in non-small cell lung cancer: No immediate impact on patient outcome. Lung Cancer. 2013;81(1):130-137.
18. Ilie M, et al. Predictive clinical outcome of the intratumoral CD66b-positive neutrophil-to-CD8-positive T-cell ratio in patients with resectable nonsmall cell lung cancer. Cancer. 2012;118(6):1726-1737.
19. Radsak M, Iking-Konert C, Stegmaier S, Andrassy K, Hansch GM. Polymorphonuclear neutrophils as accessory cells for T-cell activation: major histocompatibility complex class II restricted antigen-dependent induction of T-cell proliferation. Immunology. 2000;101(4):521-530.
20. Ashtekar AR, Saha B. Poly's plea: membership to the club of APCs. Trends Immunol. 2003;24(9):485-490.
21. Potter NS, Harding CV. Neutrophils process exogenous bacteria via an alternate class I MHC processing pathway for presentation of peptides to T lymphocytes. J Immunol. 2001;167(5):2538-2546.
22. Reali E, et al. Polymorphonuclear neutrophils pulsed with synthetic peptides efficiently activate memory cytotoxic T lymphocytes. J Leukoc Biol. 1996;60(2):207-213.
23. Pillay J, et al. A subset of neutrophils in human systemic inflammation inhibits T cell responses through mac-1. J Clin Invest. 2012;122(1):327-336.
24. Schmielau J, Finn OJ. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res. 2001;61(12):4756-4760.
25. Munder M, et al. Suppression of T-cell functions by human granulocyte arginase. Blood. 2006;108(5):1627-1634.
26. Gorgun GT, et al. Tumor-promoting immunesuppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Blood. 2013;121(15):2975-2987.
27. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9(3):162-174.
28. Eruslanov E, et al. Circulating and tumor-infiltrating myeloid cell subsets in patients with bladder cancer. Int J Cancer. 2012;130(5):1109-1119.
29. Pignatti P, et al. Downmodulation of CXCL8/IL-8 receptors on neutrophils after recruitment in the airways. J Allergy Clin Immunol. 2005;115(1):88-94.
30. Fortunati E, Kazemier KM, Grutters JC, Koenderman L, Van den Bosch VJMM. Human neutrophils switch to an activated phenotype after homing to the lung irrespective of inflammatory disease. Clin Exp Immunol. 2009;155(3):559-566.
31. Liu CY, et al. Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14(-)/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer. J Cancer Res Clin Oncol. 2010;136(1):35-45.
32. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012;12(4):253-268.
33. Hartl D, et al. Infiltrated neutrophils acquire novel chemokine receptor expression and chemokine responsiveness in chronic inflammatory lung diseases. J Immunol. 2008;181(11):8053-8067.
34. de Kleijn S, et al. IFN-γ-stimulated neutrophils suppress lymphocyte proliferation through expression of PD-L1. PLoS One. 2013;8(8):e72249.
35. Zhu C, et al. The tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol. 2005;6(12):1245-1252.
36. van Vliet SJ, Gringhuis SI, Geijtenbeek TB, van Kooyk Y. Regulation of effector T cells by antigen-presenting cells via interaction of the C-type lectin MGL with CD45. Nat Immunol. 2006;7(11):1200-1208.
37. Rygiel TP, Meyaard L. CD200R signaling in tumor tolerance and inflammation: A tricky balance. Curr Opin Immunol. 2012;24(2):233-238.
38. Zhou L, et al. Impact of human granulocyte and monocyte isolation procedures on functional studies. Clin Vaccine Immunol. 2012;19(7):1065-1074.
39. Gao JL, et al. Impaired host defense, hematopoiesis, granulomatous inflammation and type 1-type 2 cytokine balance in mice lacking CC chemokine receptor 1. J Exp Med. 1997;185(11):1959-1968.
40. Youn JI, Collazo M, Shalova IN, Biswas SK, Gabrilovich DI. Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice. J Leukoc Biol. 2012;91(1):167-181.
41. Thewissen M, Damoiseaux J, van de Gaar J, Tervaert JW. Neutrophils and T cells: Bidirectional effects and functional interferences. Mol Immunol. 2011;48(15-16):2094-2101.
42. + regulatory T cells. Nat Immunol. 2003;4(4):330-336.
43. Kobayashi SD, Voyich JM, Whitney AR, DeLeo FR. Spontaneous neutrophil apoptosis and regulation of cell survival by granulocyte macrophage-colony stimulating factor. J Leukoc Biol. 2005;78(6):1408-1418.
44. Yoshimura T, Takahashi M. IFN-γ-mediated survival enables human neutrophils to produce MCP-1/CCL2 in response to activation by TLR ligands. J Immunol. 2007;179(3):1942-1949.
45. Lentzsch S, Gries M, Janz M, Bargou R, Dorken B, Mapara MY. Macrophage inflammatory protein 1-alpha (MIP-1α) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells. Blood. 2003;101(9):3568-3573.
46. Doedens AL, et al. Macrophage expression of hypoxia-inducible factor-1 α suppresses T-cell function and promotes tumor progression. Cancer Res. 2010;70(19):7465-7475.
47. Marigo I, et al. Tumor-induced tolerance and immune suppression depend on the C/EBPβ transcription factor. Immunity. 2010;32(6):790-802.
48. Corzo CA, et al. HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med. 2010;207(11):2439-2453.
49. + T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol. 2004;172(2):989-999.
50. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010;11(10):889-896.
51. Fridlender ZG, et al. Using macrophage activation to augment immunotherapy of established tumours. Br J Cancer. 2013;108(6):1288-1297.
52. Guiducci C, Vicari AP, Sangaletti S, Trinchieri G, Colombo MP. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res. 2005;65(8):3437-3446.
53. Nozawa H, Chiu C, Hanahan D. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci U S A. 2006;103(33):12493-12498.
54. Jablonska J, Leschner S, Westphal K, Lienenklaus S, Weiss S. Neutrophils responsive to endogenous IFN-β regulate tumor angiogenesis and growth in a mouse tumor model. J Clin Invest. 2010;120(4):1151-1164.
55. Spicer JD, et al. Neutrophils promote liver metastasis via mac-1-mediated interactions with circulating tumor cells. Cancer Res. 2012;72(16):3919-3927.
56. Sandilands GP, McCrae J, Hill K, Perry M, Baxter D. Major histocompatibility complex class II (DR) antigen and costimulatory molecules on in vitro and in vivo activated human polymorphonuclear neutrophils. Immunology. 2006;119(4):562-571.
57. Watts TH. TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol. 2005;23:23-68.
58. Shao Z, Schwarz H. CD137 ligand, a member of the tumor necrosis factor family, regulates immune responses via reverse signal transduction. J Leukoc Biol. 2011;89(1):21-29.
59. Chacon JA, et al. Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy. PLoS One. 2013;8(4):e60031.
60. Hernandez-Chacon JA, et al. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function. J Immunother. 2011;34(3):236-250.
61. Musiani P, et al. Role of neutrophils and lymphocytes in inhibition of a mouse mammary adenocarcinoma engineered to release IL-2, IL-4, IL-7, IL-10, IFN-α, IFN-γ, and TNF-α. Lab Invest. 1996;74(1):146-157.
62. Giovarelli M, et al. Tumor rejection and immune memory elicited by locally released LEC chemokine are associated with an impressive recruitment of APCs, lymphocytes, and granulocytes. J Immunol. 2000;164(6):3200-3206.
63. Colombo MP, et al. Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. J Exp Med. 1991;173(4):889-897.
64. Suttmann H, et al. Neutrophil granulocytes are required for effective bacillus calmette-guerin immunotherapy of bladder cancer and orchestrate local immune responses. Cancer Res. 2006;66(16):8250-8257.
65. Kousis PC, Henderson BW, Maier PG, Gollnick SO. Photodynamic therapy enhancement of antitumor immunity is regulated by neutrophils. Cancer Res. 2007;67(21):10501-10510.
66. Mishalian I, Bayuh R, Levy L, Zolotarov L, Michaeli J, Fridlender ZG. Tumor-associated neutrophils (TAN) develop pro-tumorigenic properties during tumor progression. Cancer Immunol Immunother. 2013;62(11):1745-1756.
67. Frevert CW, Wong VA, Goodman RB, Goodwin R, Martin TR. Rapid fluorescence-based measurement of neutrophil migration in vitro. J Immunol Methods. 1998;213(1):41-52.